Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001493152-24-022030

← back to feed
Filed
May 31, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · May 30, 2024 4.46M sh
Long Term Debt Q2 2024 · Apr 30, 2024 $3M
Long Term Debt Q2 2024 · Oct 31, 2023 $2.95M
Short Term Debt Q2 2024 · Apr 30, 2024 $2.91M
Short Term Debt Q2 2024 · Oct 31, 2023 $480K
Current Liabilities Q2 2024 · Apr 30, 2024 $10.41M
Current Liabilities Q2 2024 · Oct 31, 2023 $4.85M
Total Liabilities Q2 2024 · Apr 30, 2024 $14.65M
Total Liabilities Q2 2024 · Oct 31, 2023 $9.43M
Current Assets Q2 2024 · Apr 30, 2024 $2.12M
Current Assets Q2 2024 · Oct 31, 2023 $3.18M
Total Assets Q2 2024 · Apr 30, 2024 $7.09M
Total Assets Q2 2024 · Oct 31, 2023 $8.34M
Net Income Q2 2024 · Oct 31, 2023 −$5.4M
Net Income Q2 2024 · Apr 30, 2023 −$1.41M
Net Income Q2 2024 · Apr 30, 2023 −$2.6M
Net Income Q2 2024 · Jan 31, 2023 −$1.19M
Shares Diluted Q2 2024 · Apr 30, 2023 4.43M sh
Shares Diluted Q2 2024 · Apr 30, 2023 4.43M sh
Capex Q2 2024 · Apr 30, 2023 $14.27K
Operating Cash Flow Q2 2024 · Apr 30, 2023 −$1.61M
Stockholders Equity Q2 2024 · Apr 30, 2023 $885.04K
Stockholders Equity Q2 2024 · Jan 31, 2023 $1.91M
Stockholders Equity Q2 2024 · Oct 31, 2022 $2.84M
Eps Diluted Q2 2024 · Apr 30, 2023 −$0.32
Eps Diluted Q2 2024 · Apr 30, 2023 −$0.59
Eps Basic restated Q2 2024 · Apr 30, 2023 −$0.32
Eps Basic restated Q2 2024 · Apr 30, 2023 −$0.59
Sga Expense Q2 2024 · Apr 30, 2023 $1.54M
Sga Expense Q2 2024 · Apr 30, 2023 $2.96M
Rd Expense Q2 2024 · Apr 30, 2023 $66.45K
Rd Expense Q2 2024 · Apr 30, 2023 $73.28K
Operating Income Q2 2024 · Apr 30, 2023 −$1.36M
Operating Income Q2 2024 · Apr 30, 2023 −$2.51M
Gross Profit Q2 2024 · Apr 30, 2023 $245.21K
Gross Profit Q2 2024 · Apr 30, 2023 $522.73K
Cost Of Revenue Q2 2024 · Apr 30, 2023 $62.63K
Cost Of Revenue Q2 2024 · Apr 30, 2023 $129.15K
Revenue Q2 2024 · Apr 30, 2023 $307.84K
Revenue Q2 2024 · Apr 30, 2023 $651.87K